Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BioElectronics Corp. (OTC: BIEL).

Full DD Report for BIEL

You must become a subscriber to view this report.


Recent News from (OTC: BIEL)

BioElectronics Receives FDA Pre-Submission Approval for its Relief of Musculoskeletal Pain Market Clearance Application
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9 th , 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program ...
Source: GlobeNewswire
Date: May, 11 2018 08:30
BioElectronics Meeting with FDA to Expand Indications for Products, Company Review
NEW YORK, NY / ACCESSWIRE / May 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on BioElectronics Corporation (OTC PINK: BIEL), a leader in non-...
Source: ACCESSWIRE IA
Date: May, 03 2018 08:05
BioElectronics to Meet with FDA To Seek Expanded OTC Clearances
FREDERICK, MD, May 02, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two meetings have been scheduled with the US Food and Drug Administration (FDA) to seek expanded over-the-counter (OTC) clearances for their drug-free, w...
Source: GlobeNewswire
Date: May, 02 2018 08:00
BioElectronics VP of Sales Discusses Pre & Post-operative Pain Relief Surgical Program in "Stock Day" Interview
PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire was thrilled to have Keith Nalepka, VP of Marketing & Sales at BioElectronics (OTC Pink:BIEL) (“the Company”), return to the “Stock Day” podcast. The company has been working hard lately to expand th...
Source: GlobeNewswire
Date: April, 26 2018 08:00
BioElectronics Announces Knee Replacement Clinical Study
FREDERICK, MD, March 19, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL),  www.bielcorp.com  is pleased to announce the commencement of a clinical study investigating the efficacy of its RecoveryRx® device for postoperative pain management and r...
Source: GlobeNewswire
Date: March, 19 2018 08:30
BioElectronics Vice President of Sales Discusses Opioids and the Alternative Drug Free ActiPatch® Pain Therapy
PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) -- T he Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews o...
Source: GlobeNewswire
Date: January, 22 2018 08:30
BioElectronics Announces Expanded Menstrual Pain Study
FREDERICK, MD, Jan. 16, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL),  www.bielcorp.com  is pleased to announce the commencement of an independent clinical study to investigate the efficacy of the Allay® Menstrual Pain device. The study will be take pl...
Source: GlobeNewswire
Date: January, 16 2018 08:30
BioElectronics and CARE Pharmacies to Provide Pain Consultations and ActiPatch, the Drug Free Alternative to Opioids
FREDERICK, MD, Jan. 09, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today that CARE Pharmacies has committed to introducing ActiPatch, Musculoskeletal Pain Therapy medical ...
Source: GlobeNewswire
Date: January, 09 2018 10:04
BioElectronics ActiPatch Drug Free Pain Therapy Receives United Kingdom National Health System Payment Coverage
FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government funded public health service, National Health Syst...
Source: GlobeNewswire
Date: January, 04 2018 07:00
BioElectronics Announces ActiPatch: Over-The-Counter Alternative to Opioids
FREDERICK, MD, Dec. 12, 2017 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today the launch of ActiPatch for Over-The-Counter, drug-free pain relief as an alternative to Opioids. ...
Source: GlobeNewswire
Date: December, 12 2017 08:30

 


About BioElectronics Corp. (OTC: BIEL)

Logo for BioElectronics Corp. (OTC: BIEL)

lt p gt BioElectronics Corporation develops, manufactures, markets and sells consumer medical electronic devices that have both a high efficacy and safety profile for acute and chronic pain. Along with the added benefit of an unmatched cost/benefit ratio, the Company s innovative, miniaturized technology contains an embedded microchip and battery that deliver pulsed electromagnetic field energy, a clinically proven and widely accepted anti inflammatory and pain relief therapy that has only been possible to obtain from large, facility based equipment. BioElectronics markets and sells its current products under the brand names ActiPatch Musculoskeletal Pain Relief, Allay Menstrual Pain Therapy, RecoveryRx Chronic Wounds and Postoperative Recovery, and HealFast Therapy for cats, dogs and horses. The company is headquartered in Frederick, Maryland, USA. BioElectronics is changing the way people heal around the world. Pain has a significant impact on quality of life and with our expanding international presence we are touching the lives of individuals suffering from pain and edema worldwide. Our vision is to provide our highly effective and safe technological solution to pain. We received the Wall Street Journal Technology Innovation Awards with our unique anti inflammatory technology that reduces pain and edema. This technology is the platform for everything that we do. Our current strategic vision is to develop a number of strong brands that build upon our technological platform. Currently, the main applications are aimed at the OTC markets for back pain, knee pain and menstrual pain. We hope to introduce our technology to new markets and additional countries in the near future. lt /p gt

 

 

 

Current Management

  • Andrew A. Whelan / President, CEO
  • Sariah Glosenger /
  • Patricia A Whelan /

Current Share Structure

  • Market Cap: $15,124,782 - 03/20/2018
  • Authorized: 15,000,000,000 - 09/30/2016
  • Issue and Outstanding: 12,603,985,010 - 09/30/2016
  • Float: 7,000,000,000 - 06/04/2015

 


Recent Filings from (OTC: BIEL)

Quarterly Report - UNAUDITED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016
Filing Type: Quarterly Report - UNAUDITED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2Filing Source: OTC Markets
Filing Date: November, 14 2017
Quarterly Report - OTC PINK BASIC DISCLOSURE STATEMENT SEPTEMBER 30, 2017
Filing Type: Quarterly Report - OTC PINK BASIC DISCLOSURE STATEMENT SEPTEMBER 30, 2017Filing Source: OTC Markets
Filing Date: November, 14 2017
Quarterly Report - OTC PINK BASIC DISCLOSURE STATEMENT JUNE 30, 2017
Filing Type: Quarterly Report - OTC PINK BASIC DISCLOSURE STATEMENT JUNE 30, 2017Filing Source: OTC Markets
Filing Date: August, 15 2017
Quarterly Report - UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2017 AND 2016
Filing Type: Quarterly Report - UNAUDITED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2017 AND 2016Filing Source: OTC Markets
Filing Date: August, 15 2017
Quarterly Report - UNAUDITED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016
Filing Type: Quarterly Report - UNAUDITED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016Filing Source: OTC Markets
Filing Date: May, 16 2017
Quarterly Report - Basic Disclosure Statement Q1- 2017
Filing Type: Quarterly Report - Basic Disclosure Statement Q1- 2017Filing Source: OTC Markets
Filing Date: May, 15 2017
Attorney Letter with Respect to Current Information - OTC Markets Legal Opinion BioElectronics Corp May 1, 2017
Filing Type: Attorney Letter with Respect to Current Information - OTC Markets Legal Opinion BioElectronics Corp Filing Source: OTC Markets
Filing Date: May, 01 2017
Annual Report - UNAUDITED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2016 AND 2015
Filing Type: Annual Report - UNAUDITED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2016 AND 2015Filing Source: OTC Markets
Filing Date: March, 31 2017
Officer/Director Disclosure - BASIC DISCLOSURE STATEMENT
Filing Type: Officer/Director Disclosure - BASIC DISCLOSURE STATEMENTFiling Source: OTC Markets
Filing Date: March, 31 2017
Quarterly Report - BASIC DISCLOSURE
Filing Type: Quarterly Report - BASIC DISCLOSUREFiling Source: OTC Markets
Filing Date: November, 16 2016

 

 


Daily Technical Chart for (OTC: BIEL)

Daily Technical Chart for (OTC: BIEL)


Stay tuned for daily updates and more on (OTC: BIEL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BIEL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIEL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BIEL and does not buy, sell, or trade any shares of BIEL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/